News

Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the last five sessions. in which Tempus is the third-largest position behind Tesla and SpaceX rose 4.3%.

ARK shifted more than $50 million into Block and Rocket Lab while trimming several high-profile growth names.

Robinhood upgraded, Uber initiated: Wall Street's top analyst calls

Nvidia was ARK’s biggest August purchase, with roughly 548,000 shares added during the month.

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

Tempus AI (NasdaqGS:TEM) received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled tool that flags signs of pulmonary hypertension from standard ECGs. The newly cleared product is the third FDA-cleared offering in Tempus AI's cardiovascular portfolio, expanding the company beyond its core oncology genomics focus. Tempus ECG-PH is designed to help clinicians identify a condition that can be challenging to diagnose using conventional methods, addressing a key unmet need in cardiovascular...

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.

Polovin's sale of 30,075 shares was non-discretionary and tied to tax withholding from RSU vesting.

This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.

Tempus AI stock has surged over the past month, yet the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to shares trading at a roughly 33.1% discount, while market based multiples lean expensive and the broader checks do not suggest a clear bargain. Tempus AI has returned about 54.8% over the past month, which puts extra focus on whether that jump is already pricing in much of the good news. The positive cancer vaccine trial linked to its planned...

Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.

Tempus AI Inc (TEM) reports strong Q2 2026 results with record revenue, FDA approval for xT CDx, and a major BioNTech partnership, driving a raised outlook for 25% annual growth.

Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cathie Wood's investment fund is heavily invested in SpaceX stock.

Cathie Wood, CEO of Ark Investment Management, is known for buying her favorite growth stocks during sharp pullbacks. That's exactly what she's doing with Tempus AI (TEM) after the healthcare technology stock tumbled 14% over the past week. In 2025, the flagship Ark Innovation ETF gained ...

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI (NasdaqGS:TEM) agreed to acquire cancer monitoring company Personalis in a deal valued at about US$1.5b. The transaction is focused on expanding Tempus AI's presence in minimal residual disease (MRD) testing and precision oncology. The company plans to combine Personalis' MRD technology with its existing AI driven precision oncology platform. For investors following Tempus AI, this deal highlights how central MRD testing and precision oncology have become in cancer care. Tempus AI...

Tempus will pay a 5.6% premium to integrate Personalis' cancer-testing platform into its AI-enabled oncology business.

Tempus AI (TEM) agreed to acquire cancer test maker Personalis (PSNL) in a $1.5 billion deal that Ne

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Tempus AI stock has jumped 18.6% over the past week, yet the valuation picture is mixed, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader checks suggest the shares are not a clear bargain. The 18.6% gain in the past week signals that expectations around Tempus AI have been reset quickly. This can leave new buyers with less room for error if sentiment cools. Strong revenue growth and expanding data and AI partnerships can support long...

Tempus AI, Inc. (NASDAQ:TEM) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 11, 2026, Tempus AI, Inc. (NASDAQ:TEM) announced that a multi-center validation of its artificial intelligence ECG software for predicting one-year atrial fibrillation or flutter risk was published in Heart Rhythm. The company stated the […]

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Crushing the Market With Surging Returns. Tempus AI saw its share prices jump by 10 percent on Thursday to finish at $52.56 apiece, as investors cheered its formation of a consortium alongside two health institutions to support the development of an open-source digital pathology platform […]